Bio-Techne Corporation (TECH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bio-Techne Corporation (TECH) Healthcare & Pipeline Overview

Bio-Techne Corporation is a prominent biotechnology firm specializing in life science reagents, instruments, and services, with a strong emphasis on research and clinical diagnostics, positioning itself as a key player in the global healthcare landscape.

What Is the Investment Thesis for TECH?

Bio-Techne Corporation presents a compelling investment thesis characterized by robust growth drivers and solid financial metrics. With a market capitalization of $11.4B and a P/E ratio of 68.80, the company demonstrates significant profitability, evidenced by a gross margin of 65.0% and a profit margin of 9.0%. Key growth catalysts include the increasing demand for advanced diagnostic solutions and the expansion of their Protein Sciences segment, which is expected to benefit from the growing focus on personalized medicine and cell and gene therapies. Additionally, Bio-Techne's commitment to innovation and strategic acquisitions positions it favorably against competitors such as Moderna, Inc. (MRNA) and Exelixis, Inc. (EXEL). However, investors should remain cautious of potential risks, including regulatory challenges and market volatility, which could impact the company’s performance in the near term.

Based on FMP financials and quantitative analysis

TECH Key Highlights

Market cap of $11.4B reflects strong market presence and investor confidence.

• P/E ratio of 68.80 indicates high growth expectations compared to industry peers.
• Gross margin of 65.0% showcases operational efficiency and strong product demand.
• Profit margin of 9.0% highlights profitability amidst competitive pressures.
• Beta of 1.49 suggests higher volatility compared to the broader market.

Who Are TECH's Competitors?

TECH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TECH's Key Strengths?

Strong market position with a diverse product portfolio.

• High gross margins indicating operational efficiency.
• Established brand reputation in the biotechnology sector.
• Robust R&D capabilities driving innovation and growth.

What Are TECH's Weaknesses?

High P/E ratio may indicate overvaluation compared to peers.

• Dependence on a limited number of key product lines.
• Profit margins may be affected by increasing competition.
• Potential vulnerability to regulatory changes in the healthcare sector.

What Could Drive TECH Stock Higher?

Launch of new diagnostic products expected to drive revenue growth in 2026.

• Expansion of the Protein Sciences segment to meet rising demand for cell and gene therapies.
• Strategic partnerships with research institutions to enhance product development capabilities.
• Increased investment in R&D to innovate new life science reagents.

What Are the Key Risks for TECH?

Regulatory changes could impact product approvals and market access.

• Intense competition may pressure pricing and market share.
• Economic downturns could reduce funding for research and diagnostics.
• Supply chain disruptions may affect product availability and delivery.

What Are the Growth Opportunities for TECH?

• Growth opportunity 1: The global market for life science reagents is projected to grow at a CAGR of 10.5% from 2023 to 2028, driven by increased research funding and advancements in biotechnology. Bio-Techne's extensive portfolio of reagents positions it to capture a significant share of this expanding market, particularly in therapeutic areas such as oncology and immunology.
• Growth opportunity 2: The diagnostics market, particularly molecular diagnostics, is expected to reach $11.8 billion by 2027, growing at a CAGR of 8.9%. Bio-Techne's focus on developing innovative diagnostic products, including exosome-based assays and advanced tissue-based hybridization assays, positions the company to benefit from this upward trend.
• Growth opportunity 3: Bio-Techne's Protein Sciences segment is poised for growth as the demand for cell and gene therapies increases. The market for cell and gene therapy is projected to reach $25 billion by 2026, and Bio-Techne's expertise in providing essential reagents and tools for these therapies will be a key driver of revenue.
• Growth opportunity 4: Expansion into emerging markets presents a significant growth avenue for Bio-Techne. As healthcare infrastructure improves in regions such as Asia-Pacific and Latin America, the demand for high-quality life science products is expected to rise, allowing Bio-Techne to increase its global footprint.
• Growth opportunity 5: Strategic acquisitions and partnerships can enhance Bio-Techne's product offerings and market reach. The company has a history of successful acquisitions, which have bolstered its capabilities in diagnostics and genomics, and future acquisitions could further strengthen its competitive position.

What Threats Does TECH Face?

• Intense competition from established and emerging biotechnology firms.
• Regulatory challenges impacting product development and sales.
• Market volatility affecting customer spending on research and diagnostics.
• Rapid technological advancements may outpace company innovations.

What Are TECH's Competitive Advantages?

• Strong brand recognition through established product lines and reputation.
• Extensive intellectual property portfolio protecting proprietary technologies.
• Robust R&D capabilities driving innovation and product development.
• Diverse product offerings catering to multiple segments within healthcare.
• Established relationships with key customers and industry stakeholders.

What Does TECH Do?

Founded in 1976, Bio-Techne Corporation, originally known as Techne Corporation, has evolved into a significant player in the biotechnology sector, headquartered in Minneapolis, Minnesota. The company specializes in developing, manufacturing, and selling a wide array of life science reagents, instruments, and services tailored for both research and clinical diagnostic markets. Bio-Techne operates through two primary segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is dedicated to producing biological reagents that are crucial for life science research, diagnostics, and cell and gene therapy, including cytokines, growth factors, antibodies, and small molecules. It also offers advanced proteomic analytical tools designed for automated workflows, enhancing the efficiency of protein analysis. The Diagnostics and Genomics segment focuses on creating diagnostic products such as controls, calibrators, and assays for regulated diagnostics markets, including exosome-based molecular diagnostics and advanced tissue-based assays. The company’s diverse product offerings are marketed under several well-known brands, including R&D Systems, Tocris Biosciences, and Novus Biologicals. Since its rebranding in 2014, Bio-Techne has continued to expand its global reach and product portfolio, solidifying its position as a leader in the biotechnology industry.

What Products and Services Does TECH Offer?

• Develops and manufactures life science reagents for research and clinical diagnostics.
• Offers a wide range of instruments and tools for protein analysis and diagnostics.
• Provides diagnostic products for regulated markets, including assays and controls.
• Focuses on cell and gene therapy solutions with innovative reagents and technologies.
• Markets products under several reputable brands, enhancing brand recognition.
• Serves global markets, providing solutions for researchers and clinicians.

How Does TECH Make Money?

• Generates revenue through the sale of life science reagents and diagnostic products.
• Offers instruments and analytical tools that complement its reagent sales.
• Engages in strategic partnerships and collaborations to expand product offerings.
• Focuses on R&D to innovate and develop new products for emerging market needs.
• Utilizes a multi-channel distribution strategy to reach diverse customer segments.

What Industry Does TECH Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in research and development, increased funding for healthcare innovation, and a rising demand for personalized medicine. As a key player in this sector, Bio-Techne Corporation is well-positioned to capitalize on these trends, particularly in the diagnostics and life sciences markets, which are projected to expand significantly over the next few years.

Who Are TECH's Key Customers?

• Research institutions and universities conducting life science research.
• Clinical laboratories performing diagnostic testing and analysis.
• Pharmaceutical and biotechnology companies developing therapeutics.
• Healthcare providers requiring advanced diagnostic solutions.
• Government and non-profit organizations focused on healthcare research.

Over the past six months, Bio-Techne Corporation insiders filed 15 SEC Form 4 transactions — 3 sales and 12 purchases. On net that is roughly 301K shares acquired (about $783K) — insiders putting money in tends to read as conviction.

Wall Street analysts project Bio-Techne Corporation revenue of about $1.21B for fiscal 2026, with EPS near $1.92. The estimate reflects 10 contributing analysts.

Bio-Techne Corporation has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.9% above estimates on average.

Bio-Techne Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 15.28 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Bio-Techne Corporation stands at 8.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.0%, showing how much profit it generates from its asset base. TECH trades at a trailing price-to-earnings ratio of 61.92, above the Healthcare sector average of ~23x. Its free cash flow yield is 0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.6%, the inverse of the P/E and a quick read on earnings relative to price.

Bio-Techne Corporation (TECH) Valuation Context

Valued at $11.4B, TECH is classified as a large-cap stock. Relative to its peer group, TECH's quantitative score of 94/100 is above the peer average of 60/100.

TECH Revenue & Earnings Trend

In Q1 2026, TECH generated $311.4M in top-line revenue, marking a sequential increase of 5.3%. The company recorded net income of $51.1M, with diluted EPS of $0.33. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, TECH averaged $0.17 in diluted EPS.

Company Profile

Bio-Techne Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Kim Kelderman. TECH has traded publicly since 1989.

TECH Financials

TECH Latest News

TECH Analyst Consensus

TECH MoonshotScore

Latest Bio-Techne Corporation Analysis

Common Questions About TECH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources